All In Biotech

Free tool

FAERS Monitor: Namzaric

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206439 or its brand name (Namzaric, Donepezil Hydrochloride, Memantine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

608

Serious

261

43% of reports

Hospitalization

117

Death reported

72

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death58
  • dizziness58
  • confusional state48
  • drug ineffective42
  • fall42
  • hallucination38
  • fatigue37
  • diarrhoea36
  • nausea33
  • vomiting32
  • off label use26
  • malaise23
  • decreased appetite21
  • condition aggravated19
  • asthenia18

Reports by year received

View as table
YearReports
20159
201650
2017156
201876
201999
202073
202143
202232
202323
202423
202516
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,551 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hallucinationSignal3817.512.8575
confusional stateSignal4810.37.8396
fallSignal424.43.3107
dizzinessSignal584.03.1132
decreased appetiteSignal213.12.129
vomitingSignal322.41.724
deathSignal582.31.844
condition aggravatedSignal192.21.411
diarrhoea361.91.416
malaise231.81.28
asthenia181.71.14
fatigue371.61.29
nausea331.41.04
drug ineffective421.10.80
off label use261.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.